Carolyn Bertozzi returns to Eli Lilly board of directors
Indianapolis: The board of directors of Eli Lilly and Company has elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees.
"On behalf of Lilly and the entire board, I would like to welcome Carolyn back to Lilly," said David A. Ricks , Lilly chair and CEO. "Carolyn is a Nobel Prize-winning chemist whose work has fundamentally changed how we think about developing targeted medicines, particularly in cancer. As we continue to pioneer new approaches in oncology and immunology, her perspective will be invaluable. We're fortunate to have her back as we work to deliver more breakthrough medicines to patients."
Read also: Eli Lilly Jaypirca met its primary endpoint in head-to-head Phase 3 study versus Imbruvica
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.